GLP-1 Grug: What are brand names of Semaglutide？

GLP-1

Grug:

What

Semaglutide？

are

brand

names

of

-By Polypeptide.ltd

Authoritative source：PubChem

Semaglutide is a medication used for the treatment of type 2 diabetes and for long-term weight management in individuals with obesity or excess weight. It belongs to the class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. Developed by Novo Nordisk, semaglutide is designed to mimic the action of the GLP-1 hormone, which is released after you eat and signals to your brain that you are full. It also slows the rate at which the stomach empties after eating, which leads to feelings of fullness for longer.

There are currently three FDA-approved semaglutide products, the brand name are Ozempic,

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

Wegovy and Rybelsus:

Ozempic is an injection form of semaglutide used to lower blood sugar levels in adults with type 2 diabetes mellitus, in addition to diet and exercise. Ozempic is also approved to reduce the risk of heart attack, stroke, or death in adults with type 2 diabetes mellitus and known heart disease.

Wegovy is an injection version of semaglutide. Wegovy injection is approved to help adults and children aged 12 years and older with obesity or some adults with excess weight (overweight), who also have weight-related medical problems, to lose weight and keep the weight off, in addition to diet and exercise.

Rybelsus is an oral version of semaglutide used for Type 2 diabetes. Currently, it’s the only medication in the GLP-1 agonist class that isn’t injected.

The active ingredients of these medications are semaglutide powder. All three medications are only available with a prescription. If you want to produce the medications and build your own brand.

Buying semaglutide powder bulk from Polypeptide.Ltd will get a good price.

Reference citations [1] Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group.”Once-Weekly Semaglutide in Adults with Overweight or Obesity.”N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.PMID: 33567185 [2] Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators.”Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.”JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.PMID: 35015037 [3] Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators.”Tirzepatide versus Semaglutide Once Weekly in

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

Patients with Type 2 Diabetes.”N Engl J Med. 2021 Aug 10.1056/NEJMoa2107519. Epub 2021 Jun 25.PMID: 34170647

5;385(6):503-515.

doi:

[4] Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S; STEP TEENS Investigators.”Once-Weekly Semaglutide in Adolescents with Obesity.”N Engl J Med. 2022 Dec 15;387(24):2245-2257. doi: 10.1056/NEJMoa2208601. Epub 2022 Nov 2.PMID: 36322838 [5] Smits MM, Van Raalte DH.”Safety of Semaglutide.”Front Endocrinol (Lausanne). 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. eCollection 2021.PMID: 34305810 [6] Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators.”Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.”JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.PMID: 33755728 [7] O’Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH.”Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.”Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16.PMID: 30122305 [8 ]Chao AM, Tronieri JS, Amaro A, Wadden TA.”Semaglutide for the treatment of obesity.”Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21.PMID: 34942372 [9] Singh G, Krauthamer M, Bjalme-Evans M.”Wegovy (semaglutide): a new weight loss drug for chronic weight management.”J Investig Med. 2022 Jan;70(1):5-13. doi: 10.1136/jim-2021-001952.

Epub 2021 Oct 27.PMID: 34706925 [10] Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O’Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators.”Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.”JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831.PMID: 33625476 [11] Christou GA, Katsiki N, Blundell J, Fruhbeck G, Kiortsis DN.”Semaglutide as a promising antiobesity drug.”Obes Rev. 2019 Jun;20(6):805-815. doi: 10.1111/obr.12839. Epub 2019 Feb

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/

15.PMID: 30768766 [12] Meier JJ.”Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.”Front Endocrinol (Lausanne). 2021 Jun 25;12:645617. doi: 10.3389/fendo.2021.645617. eCollection 2021.PMID: 34248838 [13] Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group.”Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.”Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10.PMID: 36216945 [14] Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators.”Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.”N Engl J Med. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11.PMID: 31185157 [15] Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group.”Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.”Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725.

Epub 2022 May 19.PMID: 35441470

Custom Synthesis Peptide Manufacturers

https://www.polypeptide.ltd/